Evidence map›Paper›PMID 37971243›Full record

Trial reportAntimicrobial agents and chemotherapy2023

Safety, tolerability, and pharmacokinetics of ibrexafungerp in healthy Chinese subjects: a randomized, double-blind, placebo-controlled phase 1 trial.

Xiaoyan Liu, Rui Zhang, Rong Li, Qiong Wu, Chao Pan, Xiangqing Yu, Yuhui Liu, Benjie Wang, Shuwen Yu

Open access · hybridAbstract readRandomized Controlled TrialClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Spectrum and management of rareTherapeutic advances in infectious disease
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xiaoyan LiuPhase 1 clinical Trial Center, Qilu Hospital of Shandong University, Jinan, China.
Rui ZhangPhase 1 clinical Trial Center, Qilu Hospital of Shandong University, Jinan, China.
Rong LiPhase 1 clinical Trial Center, Qilu Hospital of Shandong University, Jinan, China.
Qiong WuJiangsu Hansoh Pharmaceutical Group Co. Ltd., Lianyungang, China.
Chao PanJiangsu Hansoh Pharmaceutical Group Co. Ltd., Lianyungang, China.
Xiangqing YuJiangsu Hansoh Pharmaceutical Group Co. Ltd., Lianyungang, China.
Yuhui LiuJiangsu Hansoh Pharmaceutical Group Co. Ltd., Lianyungang, China.
Benjie WangPhase 1 clinical Trial Center, Qilu Hospital of Shandong University, Jinan, China.
Shuwen YuPhase 1 clinical Trial Center, Qilu Hospital of Shandong University, Jinan, China.ORCID 0009-0006-4226-6239
Shandong University · CNHansoh Pharma (China) · CN

Funding

HEALTH UTILITIES IN HEPATITIS C INFECTED PATIENTSR03HS010366 · AHRQ · UNIVERSITY OF CINCINNATI · PI SHERMAN, KENNETH E · 1999 to 1999
–
AHRQ HHS R03 HS010366
6 · The paper itself

Abstract

Ibrexafungerp (code name in China: HS-10366) is a first-in-class and orally active triterpenoid antifungal agent with broad antifungal activity against

Indexed as

TriterpenesAdultArea Under CurveDose-Response Relationship, DrugDouble-Blind MethodFemaleGlycosidesHealthy VolunteersHumansMaleGlycosidesibrexafungerpTriterpenesChinesefungal infectionHS-10366ibrexafungerppharmacokineticsphase 1

Identifiers

PMID37971243
PMCPMC10720486
OpenAlexW4388723748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.